Aodhán McBride’s Post

🧬Pharmaceuticals and life sciences and healthcare services M&A is expected to accelerate in 2024, as innovative companies that can drive value attract investor interest. Read more in PwC's M&A outlook. #PwCDeals #ValueCreation #Pharma

🧬Pharmaceuticals and life sciences and healthcare services M&A is expected to accelerate in 2024, as innovative companies that can drive value attract investor interest. Read more in PwC's M&A outlook. #PwCDeals #ValueCreation #Pharma

🧬Pharmaceuticals and life sciences and healthcare services M&A is expected to accelerate in 2024, as innovative companies that can drive value attract investor interest. Read more in PwC's M&A outlook. #PwCDeals #ValueCreation #Pharma

🧬Pharmaceuticals and life sciences and healthcare services M&A is expected to accelerate in 2024, as innovative companies that can drive value attract investor interest. Read more in PwC's M&A outlook. #PwCDeals #ValueCreation #Pharma

🧬Pharmaceuticals and life sciences and healthcare services M&A is expected to accelerate in 2024, as innovative companies that can drive value attract investor interest. Read more in PwC's M&A outlook. #PwCDeals #ValueCreation #Pharma

🧬Pharmaceuticals and life sciences and healthcare services M&A is expected to accelerate in 2024, as innovative companies that can drive value attract investor interest. Read more in PwC M&A outlook. #PwCDeals #ValueCreation #Pharma

Pleased to share PwC's outlook on M&A in the healthcare and pharmaceutical sectors for 2024. We foresee a significant increase in deal-making activity, propelled by the integration of state-of-the-art technologies in drug development, study planning, and patient care. #Healthcare #Pharma #IndustryTrends #PwCAnalysis

Pharmaceuticals and life sciences and healthcare services M&A is expected to accelerate in 2024, as innovative companies that can drive value attract investor interest. Read more in our M&A outlook: https://pwc.to/3S6JONI #PwCDeals #ValueCreation Ronald Chopoorian, Christian K. Moldt, Sujay Shetty, Christine Walters

Investor interest in GLP-1 drugs, precision medicine, and consumer healthcare is likely to fuel M&A activity in 2024. Read more in our global M&A outlook: #PwCDeals #ValueCreation #Pharma https://pwcuk.smh.re/eg1 

Positive outlook to 2025??? In the last two years, the pharmaceutical development process has seen some dramatic changes. Funding challenges, clinical trial cancellations, and restructuring trends have reshaped the landscape. The biotech sector has faced a prolonged downturn, with early-stage clinical trials hit hardest due to tighter budgets and restructuring. This has led to an unprecedented wave of program cancellations, impacting not only the trials but also overall R&D strategies. Despite these setbacks, there's a silver lining with a resurgence in specific market segments like Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs). These segments continue to thrive, attracting new investments and driving M&A activity. To navigate these shifts, pharmaceutical companies are rethinking their approach, focusing on resilience, flexibility, and innovation. The biggest change? The need for agility in response to an evolving landscape, as the industry balances constraints with new opportunities. How do you think 2025 will look? #drugdiscovery #drugdevelopment #solubility #datainnovation